Oct 2026· Cancer immunology research· pp.
OF1-OF2
· 0 citations
Medicine
Abstract
In this issue, Chen and colleagues show that MHC class II expression by pancreatic ductal adenocarcinoma (PDAC) malignant cells is a robust biomarker of both local production of IFNγ from lymphocytes and intact IFNγ signaling. RAS pathway inhibition can restore malignant cell IFNγ responsiveness in some patients, and malignant cell MHC class II expression may indicate which patients could further benefit from immunotherapy. See related article by Chen et al., p. XX .
In this issue of Cancer Cell, Zhang et al. perform multi-omics profiling on a large collection of patient-derived pancreatic ductal adenocarcinoma organoids to elucidate the mechanisms underlying intrinsic resistance to KRAS inhibition. This work identifies suppression of innate immune signaling through sustained MYC a...
Borja Miguel-López, Matthias Drosten· Cancer Cell· 0 citations
Evidence is provided for a key role of TNFR1, as expressed by malignant cells, in orchestrating a pro-tumor immunosuppressive environment through secondary inflammatory mediators through secondary inflammatory mediators.
Elixabet Bolaños, Lorena Cañas-Zabala, Irene Olivera et al.· Journal of Experimental Medi...· 1 citation
It is reported that STAT3 inhibition eliminates multiple myeloma stem-like cells while eliciting hallmarks of immunogenic cell death, yet in vivo validation remains necessary before this strategy can be considered immunogenic.
In this issue of Cancer Discovery, Chen and colleagues leverage single-cell RNA sequencing of neutrophils in the tumor microenvironment of colorectal cancer liver metastases to characterize neutrophil heterogeneity within the metastatic immune landscape. They show that the glucose-deprived metastatic microenvironment d...
Lucie Droin, Hannah Garner· Cancer Discovery· 0 citations
KRAS inhibitors (KRASi) are reshaping the treatment of aggressive tumors such as pancreatic ductal adenocarcinoma (PDAC), but it is appreciated that patients will eventually acquire resistance through multiple pathways. To avoid this outcome, there is much effort to identify combination therapies that take advantage of...
Margaret E. Haerr, Katelyn T. Byrne· Cancer Research· 0 citations
Myeloid-derived suppressor cells are a pivotal component of the immunosuppressive tumor microenvironment in hematologic malignancies. Through diverse mechanisms, they promote disease progression, therapeutic resistance, and immune evasion. This comprehensive review synthesizes current evidence on the roles of myeloid-d...
Y. Nefedova, Dmitry I. Gabrilovich· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
